Mirvie, a company engaged in predicting unexpected pregnancy complications, today announced it raised $60 million in a Series B round and a total of $90 million to date. The financing was led by Decheng Capital with additional investment from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank.
The funding will support Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy. Read more.
